Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery.

Brain delivery is one of the major challenges in drug development because of the high number of patients suffering from neural diseases and the low efficiency of the treatments available. Although the blood-brain barrier (BBB) prevents most drugs from reaching their targets, molecular vectors - known as BBB shuttles - offer great promise to safely overcome this formidable obstacle. In recent years, peptide shuttles have received growing attention because of their lower cost, reduced immunogenicity, and higher chemical versatility than traditional Trojan horse antibodies and other proteins.

[1]  I. Wilhelm,et al.  In vitro models of the blood-brain barrier for the study of drug delivery to the brain. , 2014, Molecular pharmaceutics.

[2]  M. Imperiale,et al.  A novel peptide defined through phage display for therapeutic protein and vector neuronal targeting , 2005, Neurobiology of Disease.

[3]  Chen Jiang,et al.  Targeting Caspase-3 as Dual Therapeutic Benefits by RNAi Facilitating Brain-Targeted Nanoparticles in a Rat Model of Parkinson’s Disease , 2013, PloS one.

[4]  Chen Jiang,et al.  Angiopep-Conjugated Nanoparticles for Targeted Long-Term Gene Therapy of Parkinson’s Disease , 2013, Pharmaceutical Research.

[5]  A. De Vita,et al.  NIR-labeled nanoparticles engineered for brain targeting: in vivo optical imaging application and fluorescent microscopy evidences , 2010, Journal of Neural Transmission.

[6]  C. Elliger,et al.  Enhanced secretion and uptake of beta-glucuronidase improves adeno-associated viral-mediated gene therapy of mucopolysaccharidosis type VII mice. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  Qizhi Zhang,et al.  Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice. , 2014, Biomaterials.

[8]  A. Ballabio,et al.  A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA , 2013, EMBO molecular medicine.

[9]  Chen Jiang,et al.  Targeted imaging of activated caspase-3 in the central nervous system by a dual functional nano-device. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[10]  P. Verhaert,et al.  The emergence of peptides in the pharmaceutical business: From exploration to exploitation , 2014 .

[11]  J. Swann,et al.  Loss of mTOR repressors Tsc1 or Pten has divergent effects on excitatory and inhibitory synaptic transmission in single hippocampal neuron cultures , 2014, Front. Mol. Neurosci..

[12]  K. Sundqvist,et al.  Functional specialization of fibronectin-binding beta 1-integrins in T lymphocyte migration. , 1994, Journal of immunology.

[13]  Hongzhe Sun,et al.  Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway , 2002, Pharmacological Reviews.

[14]  K. Scearce-Levie,et al.  Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates , 2014, Science Translational Medicine.

[15]  Michel Demeule,et al.  High transcytosis of melanotransferrin (P97) across the blood–brain barrier , 2002, Journal of neurochemistry.

[16]  R. Samulski,et al.  Viral vectors for gene delivery to the central nervous system , 2012, Neurobiology of Disease.

[17]  W. Geldenhuys,et al.  Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers , 2011, Journal of drug targeting.

[18]  I. Zuhorn,et al.  In vivo biodistribution of prion- and GM1-targeted polymersomes following intravenous administration in mice. , 2012, Molecular pharmaceutics.

[19]  L. Di,et al.  Demystifying brain penetration in central nervous system drug discovery. Miniperspective. , 2013, Journal of medicinal chemistry.

[20]  D. Cistola,et al.  Structural features of synthetic peptides of apolipoprotein E that bind the LDL receptor. , 1995, Journal of lipid research.

[21]  Qingfeng Xiao,et al.  Dual-targeting upconversion nanoprobes across the blood-brain barrier for magnetic resonance/fluorescence imaging of intracranial glioblastoma. , 2014, ACS nano.

[22]  Chen Jiang,et al.  Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. , 2009, Biomaterials.

[23]  Shijie Cao,et al.  Angiopep-2 and activatable cell-penetrating peptide dual-functionalized nanoparticles for systemic glioma-targeting delivery. , 2014, Molecular pharmaceutics.

[24]  K. Peremans,et al.  Cell-Penetrating Peptides Selectively Cross the Blood-Brain Barrier In Vivo , 2015, PloS one.

[25]  W. Banks,et al.  Leptin enters the brain by a saturable system independent of insulin , 1996, Peptides.

[26]  T. Tarragó,et al.  Diketopiperazines as a tool for the study of transport across the blood-brain barrier (BBB) and their potential use as BBB-shuttles. , 2007, Journal of the American Chemical Society.

[27]  R. Thorne,et al.  Diffusion of macromolecules in the brain: implications for drug delivery. , 2013, Molecular pharmaceutics.

[28]  Takahiro Nomoto,et al.  Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier. , 2013, ACS nano.

[29]  S. Cabilly,et al.  The basic structure of filamentous phage and its use in the display of combinatorial peptide libraries , 1999, Methods in molecular biology.

[30]  K. Audus,et al.  Analytical and biological methods for probing the blood-brain barrier. , 2012, Annual review of analytical chemistry.

[31]  Cao Xie,et al.  Loop 2 of Ophiophagus hannah toxin b binds with neuronal nicotinic acetylcholine receptors and enhances intracranial drug delivery. , 2010, Molecular pharmaceutics.

[32]  T. Mikkelsen,et al.  Phase I Study of GRN1005 in Recurrent Malignant Glioma , 2013, Clinical Cancer Research.

[33]  Astrid Gräslund,et al.  Mechanisms of Cellular Uptake of Cell-Penetrating Peptides , 2011, Journal of biophysics.

[34]  Dawen Dong,et al.  Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. , 2014, Biomaterials.

[35]  G. Bu,et al.  Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier , 2004, Journal of Cell Science.

[36]  J. Walsh,et al.  RVG-Mediated Calpain2 Gene Silencing in the Brain Impairs Learning and Memory , 2013, NeuroMolecular Medicine.

[37]  Carlos J. Camacho,et al.  Structural and Thermodynamic Approach to Peptide Immunogenicity , 2008, PLoS Comput. Biol..

[38]  Julen Oyarzabal,et al.  In vivo, in vitro and in silico methods for small molecule transfer across the BBB. , 2009, Journal of pharmaceutical sciences.

[39]  Rongqin Huang,et al.  Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma. , 2011, Biomaterials.

[40]  M. Suh,et al.  dNP2 is a blood–brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis , 2015, Nature Communications.

[41]  P. Steeg,et al.  Uptake of ANG1005, A Novel Paclitaxel Derivative, Through the Blood-Brain Barrier into Brain and Experimental Brain Metastases of Breast Cancer , 2009, Pharmaceutical Research.

[42]  Hiroyuki Nishimori,et al.  Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. , 2011, The Journal of clinical investigation.

[43]  W. Pardridge,et al.  Blood-brain barrier transcytosis of insulin in developing rabbits , 1987, Brain Research.

[44]  S. Futaki,et al.  Arginine-rich Peptides , 2001, The Journal of Biological Chemistry.

[45]  V. Lowe,et al.  A Carrier for Non-Covalent Delivery of Functional Beta-Galactosidase and Antibodies against Amyloid Plaques and IgM to the Brain , 2011, PloS one.

[46]  G. Rougon,et al.  Chemical optimization of new ligands of the low-density lipoprotein receptor as potential vectors for central nervous system targeting. , 2012, Journal of medicinal chemistry.

[47]  B. Davidson,et al.  Transvascular delivery of small interfering RNA to the central nervous system , 2007, Nature.

[48]  M. Masserini,et al.  Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[49]  Q. Zhang,et al.  Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals. , 2011, International journal of pharmaceutics.

[50]  E. Giralt,et al.  Intracellular fate of peptide-mediated delivered cargoes. , 2013, Current pharmaceutical design.

[51]  G. Dunn,et al.  Emerging Insights into Barriers to Effective Brain Tumor Therapeutics , 2014, Front. Oncol..

[52]  T. Terasaki,et al.  Fluids and Barriers of the Cns , 2022 .

[53]  Drug targeting to the brain. , 2007, Annual review of pharmacology and toxicology.

[54]  Yikun Gao,et al.  Polyion complex micelles composed of pegylated polyasparthydrazide derivatives for siRNA delivery to the brain. , 2015, Journal of colloid and interface science.

[55]  E. Kılıç,et al.  Intravenous TAT–Bcl‐Xl is protective after middle cerebral artery occlusion in mice , 2002, Annals of neurology.

[56]  R. Jenkins,et al.  Effective intravenous therapy for neurodegenerative disease with a therapeutic enzyme and a peptide that mediates delivery to the brain. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[57]  T. Tarragó,et al.  Dual system for the central nervous system targeting and blood-brain barrier transport of a selective prolyl oligopeptidase inhibitor. , 2013, Biopolymers.

[58]  Gilberto Alves,et al.  Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[59]  V. Labhasetwar,et al.  TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. , 2008, Biomaterials.

[60]  A. Prochiantz,et al.  Antennapedia homeobox peptide regulates neural morphogenesis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[61]  C. Kuan,et al.  Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood–brain barrier , 2013, Proceedings of the National Academy of Sciences.

[62]  E. Giralt,et al.  Abbreviated nomenclature for cyclic and branched homo- and hetero-detic peptides. , 2005, The journal of peptide research : official journal of the American Peptide Society.

[63]  W. Banks,et al.  Blood to Brain and Brain to Blood Passage of Native Horseradish Peroxidase, Wheat Germ Agglutinin, and Albumin: Pharmacokinetic and Morphological Assessments , 1994, Journal of neurochemistry.

[64]  M. Wood,et al.  Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes , 2011, Nature Biotechnology.

[65]  Amit Modgil,et al.  Influence of Short-Chain Cell-Penetrating Peptides on Transport of Doxorubicin Encapsulating Receptor-Targeted Liposomes Across Brain Endothelial Barrier , 2014, Pharmaceutical Research.

[66]  Li-ping Zhan,et al.  Targeted Delivery of Proteins into the Central Nervous System Mediated by Rabies Virus Glycoprotein-Derived Peptide , 2012, Pharmaceutical Research.

[67]  Xiaoling Fang,et al.  Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. , 2011, Biomaterials.

[68]  W. Pan,et al.  Convergent trafficking pattern of leptin after endocytosis mediated by ObRa–ObRd , 2007, Journal of cellular physiology.

[69]  L. Fenart,et al.  Receptor-mediated Transcytosis of Lactoferrin through the Blood-Brain Barrier* , 1999, The Journal of Biological Chemistry.

[70]  Rongqin Huang,et al.  A leptin derived 30-amino-acid peptide modified pegylated poly-L-lysine dendrigraft for brain targeted gene delivery. , 2010, Biomaterials.

[71]  W. Pardridge,et al.  Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. , 1987, The Journal of biological chemistry.

[72]  Chong Li,et al.  Toxins and derivatives in molecular pharmaceutics: Drug delivery and targeted therapy. , 2015, Advanced drug delivery reviews.

[73]  B. Zhang,et al.  LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma. , 2013, Biomaterials.

[74]  R. Linker,et al.  Glutathione PEGylated liposomal methylprednisolone (2B3-201) attenuates CNS inflammation and degeneration in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis , 2014, Journal of Neuroimmunology.

[75]  Chen Jiang,et al.  A brain-vectored angiopep-2 based polymeric micelles for the treatment of intracranial fungal infection. , 2012, Biomaterials.

[76]  J. Scherrmann,et al.  CNS Delivery Via Adsorptive Transcytosis , 2008, The AAPS Journal.

[77]  W. Pardridge,et al.  Receptor-mediated peptide transport through the blood-brain barrier. , 1986, Endocrine reviews.

[78]  R. Béliveau,et al.  Involvement of the low‐density lipoprotein receptor‐related protein in the transcytosis of the brain delivery vector Angiopep‐2 , 2008, Journal of neurochemistry.

[79]  E. Giralt,et al.  ‘À la Carte’ Peptide Shuttles: Tools to Increase Their Passage across the Blood–Brain Barrier , 2014, ChemMedChem.

[80]  Michele Zoli,et al.  Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[81]  Pascal Tétreault,et al.  Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties. , 2014, The Journal of clinical investigation.

[82]  Angelique van den Heuvel,et al.  Glutathione PEGylated liposomes: pharmacokinetics and delivery of cargo across the blood–brain barrier in rats , 2014, Journal of drug targeting.

[83]  E. Giralt,et al.  Shuttle-mediated drug delivery to the brain. , 2011, Angewandte Chemie.

[84]  W. Pardridge,et al.  Drug and gene targeting to the brain with molecular trojan horses , 2002, Nature Reviews Drug Discovery.

[85]  Jun Qian,et al.  Up-regulating Blood Brain Barrier Permeability of Nanoparticles via Multivalent Effect , 2013, Pharmaceutical Research.

[86]  E. Bézard,et al.  Systemic gene delivery to the central nervous system using Adeno-associated virus , 2014, Front. Mol. Neurosci..

[87]  Ernest Giralt,et al.  Applying the retro-enantio approach to obtain a peptide capable of overcoming the blood-brain barrier. , 2015, Angewandte Chemie.

[88]  Pilju Youn,et al.  A Myristoylated Cell-Penetrating Peptide Bearing a Transferrin Receptor-Targeting Sequence for Neuro-Targeted siRNA Delivery , 2014, Molecular pharmaceutics.

[89]  A. Rees,et al.  Studies on the Internalization Mechanism of Cationic Cell-penetrating Peptides* , 2003, Journal of Biological Chemistry.

[90]  M. Pooga,et al.  Cell penetration by transportan. , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[91]  Xiaoli Wei,et al.  Micelle-based brain-targeted drug delivery enabled by a nicotine acetylcholine receptor ligand. , 2011, Angewandte Chemie.

[92]  Maxime Culot,et al.  Modelling of the blood–brain barrier in drug discovery and development , 2007, Nature Reviews Drug Discovery.

[93]  R. Ransohoff,et al.  Development, maintenance and disruption of the blood-brain barrier , 2013, Nature Medicine.

[94]  I. Zuhorn,et al.  Peptide-mediated blood-brain barrier transport of polymersomes. , 2012, Angewandte Chemie.

[95]  A. Brenner,et al.  Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors , 2011, Molecular Cancer Therapeutics.

[96]  D. Mishra,et al.  Drug targeting to brain: a systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB , 2013, Expert opinion on drug delivery.

[97]  J. Os,et al.  Cost of disorders of the brain in Europe 2010 , 2011, European Neuropsychopharmacology.

[98]  M. Lazdunski,et al.  Structure-function relationships and site of action of apamin, a neurotoxic polypeptide of bee venom with an action on the central nervous system. , 1975, Biochemistry.

[99]  P. Netti,et al.  Shuttle-mediated nanoparticle delivery to the blood-brain barrier. , 2013, Small.

[100]  Carl O. Pabo,et al.  Cellular uptake of the tat protein from human immunodeficiency virus , 1988, Cell.

[101]  E. Kılıç,et al.  TAT-GDNF in neurodegeneration and ischemic stroke. , 2006, CNS drug reviews.

[102]  Zhang-bao Chen,et al.  Apamin-mediated actively targeted drug delivery for treatment of spinal cord injury: more than just a concept. , 2014, Molecular pharmaceutics.

[103]  H. Gendelman,et al.  Cell-mediated drug delivery , 2011, Expert opinion on drug delivery.

[104]  Fabao Gao,et al.  Synergistic dual-ligand doxorubicin liposomes improve targeting and therapeutic efficacy of brain glioma in animals. , 2014, Molecular pharmaceutics.

[105]  Bernadette A. Thomas,et al.  Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[106]  A. Boer,et al.  Diphtheria toxin receptor-targeted brain drug delivery , 2005 .

[107]  Ronald T. Borchardt,et al.  Hydrogen Bonding Potential as a Determinant of the in Vitro and in Situ Blood–Brain Barrier Permeability of Peptides , 1994, Pharmaceutical Research.

[108]  U. Bickel,et al.  How to measure drug transport across the blood-brain barrier , 2011, NeuroRX.

[109]  R. Starzyk,et al.  Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[110]  Lanjuan Li,et al.  The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis. , 2010, Biomaterials.

[111]  H. Lei,et al.  Imaging brain tumor by dendrimer-based optical/paramagnetic nanoprobe across the blood-brain barrier. , 2011, Chemical communications.

[112]  Louise van der Weerd,et al.  Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[113]  Xinguo Jiang,et al.  Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome. , 2011, Biomaterials.

[114]  Changhua Hu,et al.  Targeted delivery of large fusion protein into hippocampal neurons by systemic administration , 2011, Journal of drug targeting.

[115]  L. Fenart,et al.  A New Function for the LDL Receptor: Transcytosis of LDL across the Blood–Brain Barrier , 1997, The Journal of cell biology.

[116]  Haibin Xia,et al.  Recombinant Human Adenovirus: Targeting to the Human Transferrin Receptor Improves Gene Transfer to Brain Microcapillary Endothelium , 2000, Journal of Virology.

[117]  Zhen Zhao,et al.  Establishment and Dysfunction of the Blood-Brain Barrier , 2015, Cell.

[118]  Gijs Kooij,et al.  Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[119]  Ernest Giralt,et al.  MiniAp‐4: A Venom‐Inspired Peptidomimetic for Brain Delivery , 2015, Angewandte Chemie.

[120]  R. Daneman,et al.  The blood-brain barrier. , 2015, Cold Spring Harbor perspectives in biology.

[121]  H. Galla,et al.  Comparison of Five Peptide Vectors for Improved Brain Delivery of the Lysosomal Enzyme Arylsulfatase A , 2014, The Journal of Neuroscience.

[122]  G. Barrett,et al.  The identification of leptin-derived peptides that are taken up by the brain , 2009, Regulatory Peptides.

[123]  Cao Xie,et al.  Retro-inverso isomer of Angiopep-2: a stable d-peptide ligand inspires brain-targeted drug delivery. , 2014, Molecular pharmaceutics.

[124]  R. Deane,et al.  Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities. , 2012, Pharmacology & therapeutics.

[125]  W. Hennink,et al.  In Vivo Methods to Study Uptake of Nanoparticles into the Brain , 2010, Pharmaceutical Research.

[126]  K. Wasan,et al.  Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. , 2004, Advanced drug delivery reviews.

[127]  E. Shusta,et al.  Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation , 2007, Pharmaceutical Research.

[128]  Dong Soo Lee,et al.  A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. , 2011, Biomaterials.

[129]  L. B. Thomsen,et al.  Macromolecular drug transport into the brain using targeted therapy , 2010, Journal of neurochemistry.

[130]  Xinguo Jiang,et al.  The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. , 2012, Biomaterials.

[131]  W. Lencer,et al.  Ganglioside GM1-mediated Transcytosis of Cholera Toxin Bypasses the Retrograde Pathway and Depends on the Structure of the Ceramide Domain* , 2013, The Journal of Biological Chemistry.

[132]  W. Pardridge,et al.  Drug Transport across the Blood–Brain Barrier , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[133]  Rongqin Huang,et al.  Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[134]  R. Béliveau,et al.  Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep‐2 , 2008, British journal of pharmacology.

[135]  Xin-guo Jiang,et al.  A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein. , 2011, Biomaterials.

[136]  J. Kreuter,et al.  Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[137]  R. Béliveau,et al.  Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1 , 2011, British Journal of Cancer.

[138]  E. Giralt,et al.  N-methyl phenylalanine-rich peptides as highly versatile blood-brain barrier shuttles. , 2010, Journal of medicinal chemistry.

[139]  Yitao Liu,et al.  Treatment of Ischemic Brain Damage by Perturbing NMDA Receptor- PSD-95 Protein Interactions , 2002, Science.

[140]  Erkki Ruoslahti,et al.  Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs , 2010, Science.

[141]  David J. Begley,et al.  Structure and function of the blood–brain barrier , 2010, Neurobiology of Disease.

[142]  B. Johansson,et al.  Altering the blood-brain barrier in the rat by intracarotid infusion of polycations: a comparison between protamine, poly-L-lysine and poly-L-arginine. , 1993, Acta physiologica Scandinavica.

[143]  A. Misra,et al.  Drug delivery to the central nervous system: a review. , 2003, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[144]  I. Brereton,et al.  NMR studies of the low‐density lipoprotein receptor‐binding peptide of apolipoprotein E bound to dodecylphosphocholine micelles , 1999, Protein science : a publication of the Protein Society.

[145]  J. Lachowicz,et al.  ANG4043, a Novel Brain-Penetrant Peptide–mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice , 2014, Molecular Cancer Therapeutics.

[146]  Ernest Giralt,et al.  Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor. , 2012, Biomaterials.

[147]  Xin-guo Jiang,et al.  Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. , 2012, Biomaterials.

[148]  H. Wong,et al.  Current approaches to enhance CNS delivery of drugs across the brain barriers , 2014, International journal of nanomedicine.

[149]  A. Lindqvist,et al.  Enhanced brain delivery of the opioid peptide DAMGO in glutathione pegylated liposomes: a microdialysis study. , 2013, Molecular pharmaceutics.

[150]  Lu Wang,et al.  Two-order targeted brain tumor imaging by using an optical/paramagnetic nanoprobe across the blood brain barrier. , 2012, ACS nano.

[151]  Liang Feng,et al.  Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. , 2011, Biomaterials.

[152]  Takashi Suzuki,et al.  Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors , 2011, Journal of neurochemistry.

[153]  Samir Mitragotri,et al.  Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies , 2014, Nature Reviews Drug Discovery.

[154]  X. Wu,et al.  Nanotechnological advances for the delivery of CNS therapeutics. , 2012, Advanced drug delivery reviews.

[155]  C. Rousselle,et al.  New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. , 2000, Molecular pharmacology.

[156]  M. Notarnicola,et al.  Low density lipoprotein receptors and polyamine levels in human colorectal adenocarcinoma , 1995, Journal of Gastroenterology.

[157]  Anirvan Ghosh,et al.  Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle , 2014, Neuron.

[158]  L. Riboni,et al.  Salvage pathways in glycosphingolipid metabolism. , 2003, Biochimie.

[159]  Michel Demeule,et al.  Identification and Design of Peptides as a New Drug Delivery System for the Brain , 2008, Journal of Pharmacology and Experimental Therapeutics.

[160]  Qianyu Zhang,et al.  Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles. , 2015, Biomaterials.

[161]  Yingkai Zhang,et al.  Poly(ethylene glycol)-block-poly(d,l-lactide acid) micelles anchored with angiopep-2 for brain-targeting delivery , 2011, Journal of drug targeting.

[162]  Xiaoli Wei,et al.  A D-peptide ligand of nicotine acetylcholine receptors for brain-targeted drug delivery. , 2015, Angewandte Chemie.

[163]  Yi Wang,et al.  Angiopep-conjugated electro-responsive hydrogel nanoparticles: therapeutic potential for epilepsy. , 2014, Angewandte Chemie.

[164]  Mikko Gynther,et al.  Prodrug Approaches for CNS Delivery , 2008, The AAPS Journal.

[165]  M. Alonso,et al.  Nanostructured biomaterials for overcoming biological barriers , 2012 .

[166]  Wei Zhang,et al.  The improved blood-brain barrier permeability of endomorphin-1 using the cell-penetrating peptide synB3 with three different linkages. , 2014, International journal of pharmaceutics.

[167]  B. Sarmento,et al.  From naturally-occurring neurotoxic agents to CNS shuttles for drug delivery. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[168]  B. Barres,et al.  The Mouse Blood-Brain Barrier Transcriptome: A New Resource for Understanding the Development and Function of Brain Endothelial Cells , 2010, PloS one.

[169]  S. Schwarze,et al.  In vivo protein transduction: delivery of a biologically active protein into the mouse. , 1999, Science.

[170]  Xiaoling Fang,et al.  Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles. , 2012, Biomaterials.

[171]  L. Ren,et al.  Tat peptide-decorated gelatin-siloxane nanoparticles for delivery of CGRP transgene in treatment of cerebral vasospasm , 2013, International journal of nanomedicine.

[172]  W. Banks.  Peptides and the blood–brain barrier , 2015, Peptides.

[173]  M A Vandelli,et al.  Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier. , 2013, Current medicinal chemistry.

[174]  W. Luk,et al.  Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target , 2011, Science Translational Medicine.

[175]  Priti Kumar,et al.  Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[176]  E. Giralt,et al.  Toward an optimal blood-brain barrier shuttle by synthesis and evaluation of peptide libraries. , 2008, Journal of medicinal chemistry.

[177]  G. P. Smith,et al.  Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. , 1985, Science.

[178]  I. Verma,et al.  Targeted delivery of proteins across the blood–brain barrier , 2007, Proceedings of the National Academy of Sciences.

[179]  Xiangning Li,et al.  Target delivery of a gene into the brain using the RVG29-oligoarginine peptide. , 2012, Biomaterials.

[180]  G. Tosi,et al.  Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[181]  R. Béliveau,et al.  New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. , 2010, Journal of medicinal chemistry.

[182]  R. Gabathuler,et al.  Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases , 2010, Neurobiology of Disease.

[183]  E. Giralt,et al.  From venoms to BBB shuttles: Synthesis and blood-brain barrier transport assessment of apamin and a nontoxic analog. , 2013, Biopolymers.

[184]  Jijin Gu,et al.  The brain targeting mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles. , 2012, Biomaterials.

[185]  P. Domaille,et al.  Structure of the minimal interface between ApoE and LRP. , 2010, Journal of molecular biology.

[186]  E. Giralt,et al.  Lipid bilayer crossing--the gate of symmetry. Water-soluble phenylproline-based blood-brain barrier shuttles. , 2015, Journal of the American Chemical Society.

[187]  W. Geldenhuys,et al.  Engineering triiodothyronine (T3) nanoparticle for use in ischemic brain stroke , 2012, Drug Delivery and Translational Research.